Event
14th Alzheimer’s & Parkinsons Drug Development Summit
Date: 3-5 February 2026
Location: Boston, MA, USA
Tom Grammatopoulos,
BD Senior Director North America
Accelerating CNS Drug Discovery with Human-Relevant Models and Advanced Screening
Axxam is attending the Alzheimer’s & Parkinson’s Drug Development Summit, a key international forum bringing together biotech, pharma, and academic leaders working to advance therapies for neurodegenerative diseases.
Neurodegeneration research poses unique challenges: complex disease biology, translational gaps between preclinical models and patients, and the urgent need for robust, predictive data early in discovery. At Axxam, we support Alzheimer’s and Parkinson’s drug discovery programs by integrating human-relevant cellular models, advanced in vitro assays, and data-driven screening strategies designed to reduce risk and improve decision-making from target validation to hit-to-lead.
Supporting Alzheimer’s & Parkinson’s Drug Discovery: How Axxam can help
Our discovery platforms are designed to address the biological and technical bottlenecks that often slow CNS drug development.
Human-Relevant Cellular Models
- iPSC-derived neuronal and glial models
- Disease-relevant cellular systems for neurodegeneration
- Improved translational relevance compared to traditional models
- Cell-based and biochemical assays tailored to CNS targets
- Functional readouts aligned with disease mechanisms
- Robust, reproducible assay validation for early discovery
- Cell-based and biochemical high-throughput screening (HTS) assays
- High-throughput and hit-to-lead capabilities
- Hit identification and profiling
Integrated Discovery Workflows
- Seamless progression from target validation to hit identification
- Cross-functional expertise in biology, screening, and data analysis
- Flexible collaboration models for biotech and pharma programs
Why Neurodegeneration requires a different discovery approach
Alzheimer’s and Parkinson’s diseases are driven by multifactorial biology involving neuronal dysfunction, protein aggregation, neuroinflammation, and synaptic failure. Traditional discovery approaches often fall short in capturing this complexity.
Axxam’s integrated discovery strategy focuses on:
- Biological relevance: choosing models and assays that reflect human disease biology
- Data quality: generating reproducible, interpretable datasets
- Early decision support: identifying promising mechanisms and compounds sooner
This approach helps discovery teams move forward with greater confidence in challenging CNS indications.
Meet us at the Alzheimer’s & Parkinson’s Drug Development Summit
We look forward to connecting with researchers, biotech innovators, and pharma teams working to advance therapies for neurodegenerative diseases.
Whether you are exploring new targets, confirming mechanisms, or scaling up screening efforts, our team is ready to discuss how Axxam can support your Alzheimer’s or Parkinson’s drug discovery program.